Key takeaways
- The share of US employers using a third-party point-solution vendor to manage GLP-1 access rose from 11% in 2024 to 28% in 2026.
What happened
A new national survey reveals that U.S. employers are rapidly implementing third-party management systems, known as "point-solution vendors," to control the skyrocketing costs of brand-name GLP-1 weight-loss medications like Wegovy and Zepbound.
According to the 2026 Pulse of the Purchaser survey published by the National Alliance of Healthcare Purchaser Coalitions (National Alliance), the share of employers utilizing a point-solution vendor to manage GLP-1 access has nearly tripled in just two years—surging from 11% in 2024 to 28% in 2026. This shift indicates that while corporate decisions to cover obesity medications have largely stabilized, employers are now focused on building aggressive gatekeeping infrastructure around those benefits.
Why it matters
For millions of U.S. workers, this shift means that having "insurance coverage" for weight-loss medications no longer guarantees easy access to them. Point-solution vendors act as strict intermediaries between the patient, their prescriber, and the insurance plan. They are hired specifically to restrict who qualifies for these expensive therapies, police prior authorizations, and enforce strict continuation guidelines.
As corporate coverage becomes increasingly difficult to navigate due to these bureaucratic layers, more patients are being priced out of their employer plans. This is driving a significant portion of U.S. buyers to bypass insurance entirely, turning instead to direct-to-consumer telehealth providers to find affordable, cash-pay alternative paths for their metabolic care.
What the data says
The National Alliance survey, which collected responses from 408 employers and purchasers in May and June 2026, highlights that the "question of coverage" has peaked. Currently, 40% of surveyed employers cover branded GLP-1 medications for obesity, and 23% are considering it. This combined 63% figure has remained relatively flat since 2024.
Instead of expanding coverage, employers are focusing entirely on containment strategies:
- The Vendor Pipeline: Beyond the 28% of employers already using a point-solution vendor, another 39% are currently considering adding one to their plan.
- The Coverage Link: Among employers that cover or are considering branded GLP-1s, a staggering 83% either use or are considering a point-solution vendor.
- Massive Cost Pressures: Data from Segal's SHAPE report explains why employers are reacting so aggressively. Plans that covered GLP-1s for obesity saw an 18.3% prescription drug cost trend in 2025, with 8.8 percentage points of that growth driven solely by GLP-1 drugs. In contrast, plans that excluded obesity GLP-1s experienced a much lower 10.5% drug trend.
- Access Hurdles: To fight these costs, 68% of employers now limit or are considering limiting GLP-1 access to narrow patient populations with high body mass indexes (BMIs) or severe documented comorbidities.
At the same time, employer interest in covering compounded alternatives remains incredibly low. Only 25% of employers cover compounded GLP-1s, while 52% state they are not considering it. This hesitation is heavily tied to regulatory shifts; the FDA removed semaglutide from its official shortage list in early 2025, which stripped away the legal foundation for widespread bulk compounding.
How it compares
The rise of corporate point solutions stands in stark contrast to the frictionless signup processes offered by direct-to-consumer telehealth platforms. While an employer-sponsored point solution may require months of documented lifestyle modifications, mandatory coaching sessions, and extensive metabolic blood panels before approving a brand-name drug, online telehealth clinics offer direct, streamlined access.
When corporate coverage is denied, patients must compare the retail cash price of brand-name drugs against out-of-pocket telehealth options:
| Option | Average Monthly Cost | Clinical Barriers | | :--- | :--- | :--- | | Brand-Name (Employer Insurance with Point Solution) | $25 - $50 (copay, if approved) | Extremely high (strict prior authorization, BMI floors, mandatory lifestyle programs) | | Brand-Name (Out-of-Pocket / Retail) | $1,000 - $1,350 | None (requires a valid prescription) | | Online Telehealth (Cash-Pay Compounded Semaglutide) | $200 - $300 | Low to Moderate (online medical screening and consultation) |
For patients facing strict employer gatekeeping or total exclusion, switching to cash-pay compounded options through specialized clinical providers has become the primary financial relief valve.
How this fits the bigger picture
This wave of corporate gatekeeping is the natural next step in an ongoing employer revolt against the high costs of weight-loss drugs. We have previously seen this play out with major retail brands; for instance, when Starbucks cut employee GLP-1 weight-loss coverage, it forced thousands of lower-wage retail workers to seek cash alternatives.
Furthermore, as we detailed in our report on how major insurers restrict GLP-1 weight loss coverage, commercial insurance providers are increasingly shifting the financial burden of these therapies onto the consumer. By inserting point-solution vendors into the benefit design, employers can technically claim they "cover" the medication on paper while practically preventing the vast majority of their workforce from qualifying for it.
To help consumers navigate this complex environment, we offer several resources to help you compare platforms, take our matching questionnaire, or research the cheapest telehealth GLP-1 cash-pay rates available today.
What happens next
Looking forward, the clinical protocols managed by these point-solution vendors are expected to become even more sophisticated. According to a landmark Peterson Health Technology Institute (PHTI) report, employer management programs are moving past simple "initiation" restrictions to develop standardized "discontinuation" protocols. This means patients who do not hit specific weight-loss percentage milestones within 12 to 16 weeks will likely see their coverage cut off automatically.
Additionally, as more clinical trials read out and the FDA reviews alternative options, employers will continue to adjust their formularies to favor the most cost-effective clinical pathways available.
CompareRx provides factual consumer information and analysis regarding telehealth services and weight-loss medications. We do not provide medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting or changing any medication regimen.